Anticoagulant activity of enoxaparin and unfractionated heparin for venous thromboembolism prophylaxis in obese patients undergoing sleeve gastrectomy.


Journal

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
ISSN: 1878-7533
Titre abrégé: Surg Obes Relat Dis
Pays: United States
ID NLM: 101233161

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 28 09 2018
revised: 02 12 2018
accepted: 12 12 2018
pubmed: 5 2 2019
medline: 21 3 2020
entrez: 5 2 2019
Statut: ppublish

Résumé

One risk of bariatric surgery is venous thromboembolism and the optimal strategy to reduce risk requires further clarification. The objectives of this study were to identify antiXa goal attainment with the institutional standard chemoprophylaxis, analyze discordance between antiXa and thrombin generation assay (TGA) in terms of adequacy of anticoagulation, and to identify correlations between patient characteristics or covariates and markers of coagulation status. Large academic medical center in Northeastern United States. A total of 60 sleeve gastrectomy patients were enrolled in this institutional review board-approved, prospective cohort study. Patients received the institutional standard prophylactic therapy (subcutaneous enoxaparin 40 mg twice daily or unfractionated heparin [UFH]). The UFH dose was weight based, 5000 units (<120 kg) or 7500 units (≥120 kg) every 8 hours. Various measures of coagulation status were measured at or near steady state. Patients receiving enoxaparin achieved goal antiXa more frequently compared with the UFH group, and statistical significance was demonstrated (93.8 % versus 4.5%, respectively; P < .0001). Target endogenous thrombin potential reduction from baseline was more frequently obtained in the enoxaparin group versus UFH (50% versus 27.7%, respectively; P = .12). AntiXa was below the limit of detection for the majority of UFH patients; while TGA suggested patients did experience anticoagulation at some level of effectiveness. Endogenous thrombin potential change in the enoxaparin group was correlated to several measures of body composition. Patients receiving enoxaparin achieved goal antiXa more often versus UFH. There was discordance between antiXa and TGA-based assessment of coagulation status. TGA may provide a more robust assessment of the adequacy of chemoprophylaxis.

Sections du résumé

BACKGROUND BACKGROUND
One risk of bariatric surgery is venous thromboembolism and the optimal strategy to reduce risk requires further clarification.
OBJECTIVES OBJECTIVE
The objectives of this study were to identify antiXa goal attainment with the institutional standard chemoprophylaxis, analyze discordance between antiXa and thrombin generation assay (TGA) in terms of adequacy of anticoagulation, and to identify correlations between patient characteristics or covariates and markers of coagulation status.
SETTING METHODS
Large academic medical center in Northeastern United States.
METHODS METHODS
A total of 60 sleeve gastrectomy patients were enrolled in this institutional review board-approved, prospective cohort study. Patients received the institutional standard prophylactic therapy (subcutaneous enoxaparin 40 mg twice daily or unfractionated heparin [UFH]). The UFH dose was weight based, 5000 units (<120 kg) or 7500 units (≥120 kg) every 8 hours. Various measures of coagulation status were measured at or near steady state.
RESULTS RESULTS
Patients receiving enoxaparin achieved goal antiXa more frequently compared with the UFH group, and statistical significance was demonstrated (93.8 % versus 4.5%, respectively; P < .0001). Target endogenous thrombin potential reduction from baseline was more frequently obtained in the enoxaparin group versus UFH (50% versus 27.7%, respectively; P = .12). AntiXa was below the limit of detection for the majority of UFH patients; while TGA suggested patients did experience anticoagulation at some level of effectiveness. Endogenous thrombin potential change in the enoxaparin group was correlated to several measures of body composition.
CONCLUSIONS CONCLUSIONS
Patients receiving enoxaparin achieved goal antiXa more often versus UFH. There was discordance between antiXa and TGA-based assessment of coagulation status. TGA may provide a more robust assessment of the adequacy of chemoprophylaxis.

Identifiants

pubmed: 30713119
pii: S1550-7289(18)31097-9
doi: 10.1016/j.soard.2018.12.014
pii:
doi:

Substances chimiques

Anticoagulants 0
Enoxaparin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

363-373

Informations de copyright

Copyright © 2018 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Luigi Brunetti (L)

Department of Pharmacy Practice, Rutgers, The State University of New Jersey, Piscataway, New Jersey; Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, New Jersey. Electronic address: brunetti@pharmacy.rutgers.edu.

Andrew Wassef (A)

Advanced Surgical and Bariatrics of New Jersey, Somerset, NJ; Department of General Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey; Bariatric Center of Excellence, Robert Wood Johnson Barnabas University Hospital, New Brunswick, New Jersey.

Ragui Sadek (R)

Advanced Surgical and Bariatrics of New Jersey, Somerset, NJ; Department of General Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey; Bariatric Center of Excellence, Robert Wood Johnson Barnabas University Hospital, New Brunswick, New Jersey.

Kiran Deshpande (K)

Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, New Jersey.

Jane Ziegler (J)

Department of Clinical and Preventive Nutrition Sciences, Rutgers, The State University of New Jersey, Newark, New Jersey.

Sung Shin Na (SS)

Department of Pharmacy Practice, Rutgers, The State University of New Jersey, Piscataway, New Jersey.

Paul Riley (P)

Diagnostica Stago, Inc., Parsippany, New Jersey.

Leonid Kagan (L)

Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, New Jersey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH